Abstract | BACKGROUND: METHOD: Two cohorts of adults aged 17-43 years were vaccinated with Twinrix according to a 0, 1, 6 months schedule and followed up for 10 years. RESULTS: One month after the primary vaccination course (Month 7), all subjects were seropositive for anti-HAV and all had anti-HBs> or = 10 mIU/ml. At month 120, 100% of subjects (N=34; N=29) in both cohorts were seropositive for anti-HAV; 94.1% and 86.2% of subjects had anti-HBs > or = 10 mIU/ml. The geometric mean concentrations (GMC; mIU/ml) were 373.9 and 674.6 in the two cohorts for anti-HAV, and 103.8 and 320.0, respectively, for anti-HBs. None of the serious adverse events reported throughout the follow-up period were considered by the investigator to be causally related to vaccination. CONCLUSIONS: Combined hepatitis A and B vaccine, Twinrix, is safe, well-tolerated and has demonstrated a highly immunogenic profile. Persistence of anti-HAV and anti-HBs antibodies in adults remains high for at least 10 years after primary vaccination.
|
Authors | K Van Herck, G Leroux-Roels, P Van Damme, K Srinivasa, B Hoet |
Journal | Travel medicine and infectious disease
(Travel Med Infect Dis)
Vol. 5
Issue 3
Pg. 171-5
(May 2007)
ISSN: 1477-8939 [Print] Netherlands |
PMID | 17448944
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Hepatitis A Vaccines
- Hepatitis Antibodies
- Hepatitis B Vaccines
- Vaccines, Combined
- twinrix
|
Topics |
- Adolescent
- Adult
- Cohort Studies
- Double-Blind Method
- Female
- Hepatitis A
(blood, prevention & control)
- Hepatitis A Vaccines
(immunology)
- Hepatitis Antibodies
(blood)
- Hepatitis B
(blood, prevention & control)
- Hepatitis B Vaccines
(immunology)
- Humans
- Male
- Middle Aged
- Travel
- Treatment Outcome
- Vaccination
- Vaccines, Combined
(immunology)
|